{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T15:47:04Z","timestamp":1771256824390,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The objective was to assess the cost-effectiveness of transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis with intermediate surgical risk in Singapore.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A de novo Markov model with three health states \u2013 stroke with long-term sequelae, no stroke, and death \u2013 was developed and simulated using Monte Carlo simulations with 10,000 iterations over a five-year time horizon from the Singapore healthcare system perspective. A 3% annual discount rate for costs and outcomes and monthly cycle lengths were used. By applying the longest available published clinical evidence, simulated patients received either TAVI or surgical aortic valve replacement (SAVR) and were at risk of adverse events (AEs) such as moderate-to-severe paravalvular aortic regurgitation (PAR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>When five-year PARTNER 2A data was applied, base-case analyses showed that the incremental cost-effectiveness ratio (ICER) for TAVI compared to SAVR was US$315,760 per quality-adjusted life year (QALY) gained. The high ICER was due to high incremental implantation and procedure costs of TAVI compared to SAVR, and marginal improvement of 0.10 QALYs as simulated mortality of TAVI exceeded SAVR at 3.75\u00a0years post-implantation. One-way sensitivity analysis showed that the ICERs were most sensitive to cost of PAR, utility values of SAVR patients, and cost of TAVI and SAVR implants and procedures. When disutilities for AEs were additionally applied, the ICER decreased to US$300,070 per QALY gained. TAVI was dominated by SAVR when the time horizon increased to 20\u00a0years. Clinical outcomes projected from one-year PARTNER S3i data further reduced the ICER to US$86,337 per QALY gained for TAVI, assuming early all-cause mortality benefits from TAVI continued to persist. This assumption was undermined when longer term data showed that TAVI\u2019s early mortality benefits diminished at five years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Limitations and conclusion<\/jats:title>\n                <jats:p>TAVI is unlikely to be cost-effective in intermediate surgical-risk patients compared to SAVR in Singapore.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-022-08369-5","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T16:02:56Z","timestamp":1659628976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness of transcatheter aortic valve implantation in patients with severe symptomatic aortic stenosis of intermediate surgical risk in Singapore"],"prefix":"10.1186","volume":"22","author":[{"given":"Rachel Su-En","family":"See-Toh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin Yi","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kush Shiv Kishore Herkshin","family":"Mahboobani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swee Sung","family":"Soon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katy","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay Woon","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivandito","family":"Kuntjoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwong","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"8369_CR1","unstructured":"American Heart Association. Aortic Stenosis Overview. 2020; https:\/\/www.heart.org\/en\/health-topics\/heart-valve-problems-and-disease\/heart-valve-problems-and-causes\/problem-aortic-valve-stenosis Accessed 2020 Mar 4"},{"key":"8369_CR2","unstructured":"National Heart Centre Singapore. Transcatheter aortic valve implantation (TAVI) - An alternative treatment for symptomatic severe aortic stenosis patients. 2017; https:\/\/www.singhealth.com.sg\/news\/medical-news\/transcatheter-aortic-valve-implantation-tavi-alternative-treatment Accessed 2020 Mar 4"},{"issue":"17","key":"8369_CR3","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","volume":"363","author":"MB Leon","year":"2010","unstructured":"Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med. 2010;363(17):1597\u2013607. https:\/\/doi.org\/10.1056\/NEJMoa1008232.","journal-title":"N Engl J Med"},{"issue":"18","key":"8369_CR4","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa1202277","volume":"366","author":"RR Makkar","year":"2012","unstructured":"Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, et al. Transcatheter Aortic-Valve Replacement for Inoperable Severe Aortic Stenosis. N Engl J Med. 2012;366(18):1696\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa1202277.","journal-title":"N Engl J Med"},{"key":"8369_CR5","doi-asserted-by":"publisher","unstructured":"Tay ELW, Lew PS, Poh KK, Saclolo R, Chia B-L, Yeo TC, et al. Demographics of severe valvular aortic stenosis in Singapore. Singapore Med J. 2013 Jan;54(1):36\u20139. https:\/\/doi.org\/10.11622\/smedj.2013009","DOI":"10.11622\/smedj.2013009"},{"key":"8369_CR6","unstructured":"Medtronic. A minimally invasive alternative for severe aortic stenosis. https:\/\/europe.medtronic.com\/xd-en\/healthcare-professionals\/therapies-procedures\/cardiovascular\/transcatheter-aortic-valve-implantation\/tavi\/about-the-therapy.html Accessed 2021 Jun 18"},{"issue":"2","key":"8369_CR7","first-page":"1","volume":"20","author":"Health Quality Ontario","year":"2020","unstructured":"Health Quality Ontario. Transcatheter Aortic Valve Implantation in Patients With Severe, Symptomatic Aortic Valve Stenosis at Intermediate Surgical Risk: A Health Technology Assessment. Ont Health Technol Assess Ser. 2020;20(2):1\u2013121.","journal-title":"Ont Health Technol Assess Ser"},{"issue":"7","key":"8369_CR8","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1161\/CIRCULATIONAHA.118.035236","volume":"139","author":"SJ Baron","year":"2019","unstructured":"Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, et al. Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk. Circulation. 2019;139(7):877\u201388. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035236.","journal-title":"Circulation"},{"issue":"7","key":"8369_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.47102\/annals-acadmedsg.2019198","volume":"49","author":"I Kuntjoro","year":"2020","unstructured":"Kuntjoro I, Tay E, Hon J, Yip J, Kong W, Poh KK, et al. Cost-Effectiveness of Transcatheter Aortic Valve Implantation in Intermediate and Low Risk Severe Aortic Stenosis Patients in Singapore. Ann Acad Med Singapore. 2020;49(7):423\u201333.","journal-title":"Ann Acad Med Singapore"},{"issue":"17","key":"8369_CR10","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1514616","volume":"374","author":"MB Leon","year":"2016","unstructured":"Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016;374(17):1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1514616.","journal-title":"N Engl J Med"},{"issue":"9","key":"8369_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1910555","volume":"382","author":"RR Makkar","year":"2020","unstructured":"Makkar RR, Thourani VH, Mack MJ, Kodali SK, Kapadia S, Webb JG, et al. Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. N Engl J Med. 2020;382(9):799\u2013809. https:\/\/doi.org\/10.1056\/NEJMoa1910555.","journal-title":"N Engl J Med"},{"issue":"14","key":"8369_CR12","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1700456","volume":"376","author":"MJ Reardon","year":"2017","unstructured":"Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, S\u00f8ndergaard L, Mumtaz M, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017;376(14):1321\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1700456.","journal-title":"N Engl J Med"},{"issue":"10034","key":"8369_CR13","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/S0140-6736(16)30073-3","volume":"387","author":"VH Thourani","year":"2016","unstructured":"Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet (London, England). 2016;387(10034):2218\u201325. https:\/\/doi.org\/10.1016\/S0140-6736(16)30073-3.","journal-title":"Lancet (London, England)"},{"key":"8369_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2020.07.029","author":"S Kodali","year":"2020","unstructured":"Kodali S. SAPIEN 3 TAVR versus surgery in intermediate risk patients: a propensity score matched analysis of 5-year outcomes [Conference Abstract]. Cardiovasc Revascularisation Med. 2020. https:\/\/doi.org\/10.1016\/j.carrev.2020.07.029.","journal-title":"Cardiovasc Revascularisation Med"},{"issue":"3","key":"8369_CR15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.athoracsur.2018.03.069","volume":"106","author":"DY Tam","year":"2018","unstructured":"Tam DY, Hughes A, Wijeysundera HC, Fremes SE. Cost-Effectiveness of Self-Expandable Transcatheter Aortic Valves in Intermediate-Risk Patients. Ann Thorac Surg. 2018;106(3):676\u201383. https:\/\/doi.org\/10.1016\/j.athoracsur.2018.03.069.","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"8369_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/13696998.2018.1559600","volume":"22","author":"G Goodall","year":"2019","unstructured":"Goodall G, Lamotte M, Ramos M, Maunoury F, Pejchalova B, de Pouvourville G. Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients. J Med Econ. 2019;22(4):289\u201396. https:\/\/doi.org\/10.1080\/13696998.2018.1559600.","journal-title":"J Med Econ"},{"key":"8369_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2147\/CEOR.S208107","volume":"11","author":"J-E Tarride","year":"2019","unstructured":"Tarride J-E, Luong T, Goodall G, Burke N, Blackhouse G. A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients. Clinicoecon Outcomes Res. 2019;11:477\u201386. https:\/\/doi.org\/10.2147\/CEOR.S208107.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"5\u20136","key":"8369_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/24748706.2017.1381357","volume":"1","author":"BP Geisler","year":"2017","unstructured":"Geisler BP, Huygens SA, Reardon MJ, Van MN, Kappetein AP, Osnabrugge RLJ, et al. Cost-Effectiveness and Projected Survival of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement for High Risk Patients in a European Setting: A Dutch Analysis Based on the CoreValve High Risk Trial. Struct Hear. 2017;1(5\u20136):267\u201374. https:\/\/doi.org\/10.1080\/24748706.2017.1381357.","journal-title":"Struct Hear"},{"issue":"19","key":"8369_CR19","first-page":"1","volume":"16","author":"Health Quality Ontario","year":"2016","unstructured":"Health Quality Ontario. Transcatheter Aortic Valve Implantation (TAVI) for Treatment of Aortic Valve Stenosis. Ont Heal Technol Assess Ser. 2016;16(19):1\u201394.","journal-title":"Ont Heal Technol Assess Ser"},{"key":"8369_CR20","doi-asserted-by":"publisher","unstructured":"Tam DY, Hughes A, Fremes SE, Youn S, Hancock-Howard RL, Coyte PC, et al. A cost-utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical risk. J Thorac Cardiovasc Surg. 2018;155(5):1978\u20131988.e1. https:\/\/doi.org\/10.1016\/j.jtcvs.2017.11.112","DOI":"10.1016\/j.jtcvs.2017.11.112"},{"issue":"25","key":"8369_CR21","doi-asserted-by":"publisher","first-page":"e1159","DOI":"10.1161\/CIR.0000000000000503","volume":"135","author":"RA Nishimura","year":"2017","unstructured":"Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA\/ACC Focused Update of the 2014 AHA\/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(25):e1159\u201395. https:\/\/doi.org\/10.1161\/CIR.0000000000000503.","journal-title":"Circulation"},{"issue":"23","key":"8369_CR22","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1161\/CIR.0000000000000029","volume":"129","author":"RA Nishimura","year":"2014","unstructured":"Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA\/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(23):2440\u201392. https:\/\/doi.org\/10.1161\/CIR.0000000000000029.","journal-title":"Circulation"},{"key":"8369_CR23","doi-asserted-by":"publisher","unstructured":"Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23 CC-Heart):2187\u20102198. https:\/\/doi.org\/10.1056\/NEJMoa1103510","DOI":"10.1056\/NEJMoa1103510"},{"issue":"19","key":"8369_CR24","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa1400590","volume":"370","author":"DH Adams","year":"2014","unstructured":"Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370(19):1790\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1400590.","journal-title":"N Engl J Med"},{"issue":"3","key":"8369_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jjcc.2017.10.008","volume":"71","author":"S Kodera","year":"2018","unstructured":"Kodera S, Kiyosue A, Ando J, Komuro I. Cost effectiveness of transcatheter aortic valve implantation in patients with aortic stenosis in Japan. J Cardiol. 2018;71(3):223\u20139. https:\/\/doi.org\/10.1016\/j.jjcc.2017.10.008.","journal-title":"J Cardiol"},{"key":"8369_CR26","unstructured":"Agency for Care Effectiveness (ACE). MEDICAL TECHNOLOGIES EVALUATION METHODS AND PROCESS GUIDE. 2022;"},{"key":"8369_CR27","unstructured":"Department of Statistics, Ministry of Trade & Industry. Population trends, 2020. 2020; https:\/\/www.singstat.gov.sg\/-\/media\/files\/publications\/population\/population2020.pdf Accessed"},{"key":"8369_CR28","unstructured":"Money Authority Singapore. Exchange Rates [Internet]. 2021. https:\/\/eservices.mas.gov.sg\/Statistics\/msb\/ExchangeRates.aspx Accessed"},{"issue":"19","key":"8369_CR29","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1093\/eurheartj\/ehs255","volume":"33","author":"AP Kappetein","year":"2012","unstructured":"Kappetein AP, Head SJ, G\u00e9n\u00e9reux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J. 2012;33(19):2403\u201318. https:\/\/doi.org\/10.1093\/eurheartj\/ehs255.","journal-title":"Eur Heart J"},{"key":"8369_CR30","unstructured":"Piazza N. An Introduction to VARC-3 Focused Update, New Endpoints and Definitions for Aortic Valve Clinical Research. Presentation (SHDS). 2018."},{"key":"8369_CR31","unstructured":"Rohatgi A. WebPlotDigitizer [Internet]. https:\/\/automeris.io\/WebPlotDigitizer\/ Accessed 2021 Nov 10"},{"key":"8369_CR32","doi-asserted-by":"publisher","unstructured":"Kapadia S, Agarwal S, Miller DC, Webb JG, Mack M, Ellis S, et al. Insights Into Timing, Risk Factors, and Outcomes of Stroke and Transient Ischemic Attack After Transcatheter Aortic Valve Replacement in the PARTNER Trial (Placement of Aortic Transcatheter Valves). Circ Cardiovasc Interv. 2016 Sep;9(9). https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.115.002981","DOI":"10.1161\/CIRCINTERVENTIONS.115.002981"},{"key":"8369_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijcard.2019.06.057","volume":"294","author":"J Zhou","year":"2019","unstructured":"Zhou J, Liew D, Duffy SJ, Walton A, Htun N, Stub D. Cost-effectiveness of transcatheter aortic valve implantation compared to surgical aortic valve replacement in the intermediate surgical risk population. Int J Cardiol. 2019;294:17\u201322. https:\/\/doi.org\/10.1016\/j.ijcard.2019.06.057.","journal-title":"Int J Cardiol"},{"issue":"8","key":"8369_CR34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/jamacardio.2017.2039","volume":"2","author":"SJ Baron","year":"2017","unstructured":"Baron SJ, Arnold SV, Wang K, Magnuson EA, Chinnakondepali K, Makkar R, et al. Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk: results From the PARTNER 2 Randomized Clinical Trial. JAMA Cardiol. 2017;2(8):837\u201345. https:\/\/doi.org\/10.1001\/jamacardio.2017.2039.","journal-title":"JAMA Cardiol"},{"key":"8369_CR35","unstructured":"Tan-Torres ET, Baltussen, R; Adam, T; Hutubessy, R; Acharya, A; Evans, DB; Murray, DB; Murray C. Making choices in health: WHO guide to cost-effectiveness analysis. Vol. 1. World Health Organization; 2003."},{"key":"8369_CR36","unstructured":"Zhang K, Garau M. International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making. OHE Consult Rep. 2020; https:\/\/www.ohe.org\/publications\/international-cost-effectiveness-thresholds-and-modifiers-hta-decision-making Accessed"},{"key":"8369_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.01815-2018Accessed","volume":"2018","author":"The National Institute for Health and Care","year":"2013","unstructured":"The National Institute for Health and Care. Guide to the methods of technology appraisal. Nice. 2013;2018:1\u201393. https:\/\/doi.org\/10.1183\/13993003.01815-2018Accessed.","journal-title":"Nice"},{"issue":"1","key":"8369_CR38","doi-asserted-by":"publisher","first-page":"1717030","DOI":"10.1080\/20016689.2020.1717030","volume":"8","author":"JA McDougall","year":"2020","unstructured":"McDougall JA, Furnback WE, Wang BCM, Mahlich J. Understanding the global measurement of willingness to pay in health. J Mark access Heal policy. 2020;8(1):1717030. https:\/\/doi.org\/10.1080\/20016689.2020.1717030.","journal-title":"J Mark access Heal policy"},{"key":"8369_CR39","doi-asserted-by":"publisher","unstructured":"Culyer A, Chalkidou K, Teerawattananon Y, Santatiwongchai B. Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays? [version 1; referees: 1 approved, 2 approved with reservations]. F1000Research. 2018;7(May). https:\/\/doi.org\/10.12688\/f1000research.13284.1","DOI":"10.12688\/f1000research.13284.1"},{"issue":"3","key":"8369_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/14737167.2021.1890587","volume":"21","author":"L-J Cheng","year":"2021","unstructured":"Cheng L-J, Wong G, Chay W-Y, Ngeow J, Tan Y, Soon SS, et al. Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1\/2 mutation status for platinum-sensitive relapsed ovarian cancer. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):441\u20138. https:\/\/doi.org\/10.1080\/14737167.2021.1890587.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"8369_CR41","unstructured":"Health Information and Quality Authority. Health Technology Assessment of transcatheter aortic valve implantation ( TAVI ) in patients with severe symptomatic aortic stenosis at low and intermediate risk of surgical complications. 2019;(November). https:\/\/www.hiqa.ie\/sites\/default\/files\/2019-12\/TAVI_HTA.pdf Accessed"},{"issue":"9","key":"8369_CR42","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s10198-021-01314-z","volume":"22","author":"V Lorenzoni","year":"2021","unstructured":"Lorenzoni V, Barbieri G, Saia F, Meucci F, Martinelli GL, Cerillo AG, et al. The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups. Eur J Heal Econ. 2021;22(9):1349\u201363. https:\/\/doi.org\/10.1007\/s10198-021-01314-z.","journal-title":"Eur J Heal Econ"},{"key":"8369_CR43","unstructured":"Norwegian Institute of Public Health. Health technology assessment of Transcatether aortic valve implantation (TAVI) as treatment of patients with severe aortic stenosis and intermediate surgical risk \u2013 Part 2. Health economic evaluation [Internet]. 2019. https:\/\/www.fhi.no\/en\/publ\/2019\/Transcatether-aortic-valve-implantation-as-treatment-of-patients-with-severe-aortic-stenosis-and-intermediate-surgical-risk\/ Accessed"},{"key":"8369_CR44","unstructured":"Healthcare Improvement Scotland. Transcatheter aortic valve implantation (TAVI) for the treatment of patients with severe symptomatic aortic stenosis who are at intermediate surgical risk. SHTG Publ. 2019;(91). https:\/\/www.healthcareimprovementscotland.org\/our_work\/technologies_and_medicines\/topics_assessed\/shtg_04-19.aspx Accessed"},{"key":"8369_CR45","doi-asserted-by":"publisher","unstructured":"Pinar E, Garc\u00eda de Lara J, Hurtado J, Robles M, Leithold G, Mart\u00ed-S\u00e1nchez B, et al. Cost-effectiveness analysis of the SAPIEN 3 transcatheter aortic valve implant in patients with symptomatic severe aortic stenosis. Rev Espa\u00f1ola Cardiol (English Ed. 2021;(x). https:\/\/doi.org\/10.1016\/j.rec.2021.02.013","DOI":"10.1016\/j.rec.2021.02.013"},{"key":"8369_CR46","unstructured":"Health Technology Wales. Evidence Appraisal Report: Transcatheter Aortic Valve implantation to treat people with severe symptomatic aortic stenosis , who are at intermediate surgical risk. 2020;(September):1\u201375. https:\/\/www.healthtechnology.wales\/wp-content\/uploads\/2020\/07\/EAR024-Transcatheter-Aortic-Valve-implantation-1.pdf Accessed"},{"key":"8369_CR47","unstructured":"EUnetHTA. Transcatheter aortic valve implantation (TAVI) for the treatment of patients at intermediate surgical risk. 2018; https:\/\/www.eunethta.eu\/wp-content\/uploads\/2018\/12\/OTCA06-TAVI-FOR-THE-TREATMENT-OFPATIENTS-AT-INTERMEDIATE-SURGICAL-RISK-FINAL-1.pdf Accessed 2020 Mar 4"},{"key":"8369_CR48","unstructured":"Medical Services Advisory Committee. Application No. 1652 \u2013 Transcatheter aortic valve implantation via transfemoral delivery for patients at intermediate risk for surgery. 2021;(March). http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/8C10EAD0A322460BCA258632000DACB7\/$File\/1652 Final PSD - Mar-Apr 2021_redacted.pdf Accessed"},{"key":"8369_CR49","unstructured":"Medical Services Advisory Committee. Application No. 1603 \u2013 Transcatheter Aortic Valve Implantation (TAVI) using SAPIEN 3 balloon-expandable valve system. 2020;(November). http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/5C3844FD549800CBCA25849300087D9F\/$File\/1603 Final PSD_Nov2020_redacted.pdf Accessed"},{"key":"8369_CR50","doi-asserted-by":"publisher","unstructured":"Baron SJ, Thourani VH, Kodali S, Arnold SV, Wang K, E.A. M, et al. Effect of SAPIEN 3 Transcatheter Valve Implantation on Health Status in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk: Results From the PARTNER S3i Trial. JACC Cardiovasc Interv. 2018;11(12):1188\u201398. https:\/\/doi.org\/10.1016\/j.jcin.2018.02.032","DOI":"10.1016\/j.jcin.2018.02.032"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08369-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-08369-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08369-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T04:06:30Z","timestamp":1659672390000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-08369-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8369"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-08369-5","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"3 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate."}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.K. and I.K. received honoraria as speakers from Edwards Lifesciences and Medtronic. All other authors declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"994"}}